BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Mundipharma Greenlights European Approval for REZZAYO® in Treating Adult Invasive Candidiasis

The approval is based on the positive results of the pivotal Phase III ReSTORE clinical trial and is supported by STRIVE's Phase II clinical trials and a...

January 01, 2024 | News

Elpiscience, Astellas Ink Deal for Novel Bispecific Macrophage Engager

The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up ...

January 01, 2024 | News

TiumBio Raises KRW 38.5B for Upcoming Clinical Data

The proceeds will fund its robust clinical programs and bolster TiumBio's financial position. Data read-outs from a Phase 2 trial of merigolix...

January 01, 2024 | News

Recbio's REC610 Shingles Vaccine Shows Positive Interim Trial Results in the Philippines

Previously, the Company conducted a GSK Shingrix® active-controlled FIH clinical trial of REC610 in the Philippines. The Interim Analysis (IA) res...

December 29, 2023 | News

Clover's SCB-219M Shows Positive Phase I Results for Chemotherapy-Induced Thrombocytopenia (CIT) Treatment

--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses t...

December 29, 2023 | News

Innovent and Xuanzhu Collaborate on Clinical Trial for Combined Therapy in Chinese Solid Tumor Treatment

Under the agreement, Innovent will supply sintilimab for the collaborated clinical trial. Xuanzhu Biopharma will conduct a Phase 1b clinical stud...

December 29, 2023 | News

Biocytogen and CtM Bio Advance in Developing Multi-Specific T Cell Engager against WT1/HLA-A02

In just one year since the start of the collaboration, the companies have identified a WT1/HLA-A02-specific T cell engager (WT1xCD3x4-1BB tri-specific anti...

December 28, 2023 | News

Nectin Therapeutics Expands Clinical Trial to Israel, Progresses Swiftly

Nectin Therapeutics Ltd., (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology t...

December 27, 2023 | News

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria. Drug resistance of anti...

December 27, 2023 | News

Asieris' APL-2301 Approved for Phase I Trials in Australia for Acinetobacter baumannii Infection

The planned clinical trial in Australia will be the first-in-human Phase I trial for APL-2301. It aims to evaluate the safety, tolerability, phar...

December 26, 2023 | News

Oncoshot Collaborates with Zhejiang Ablaze for Data-Driven Drug Development in China

This collaboration brings together complementary strengths - Oncoshot's capabilities in data analysis and insights generation with Ablaze's recent expansio...

December 26, 2023 | News

TransThera Completes First Patient Dosing in US for Global Phase 3 Trial of Tinengotinib in FGFRi Relapsed/Refractory Cholangiocarcinoma

This study is a Phase 3, randomized, controlled, global multicenter study to evaluate the efficacy and safety of oral tinengotinib versus physician's choic...

December 22, 2023 | News

Everest Medicines' Partner Calliditas Announces Nefecon® as Sole FDA-Approved Treatment for Slowing IgA Nephropathy Kidney Decline

The FDA approval is for adults with primary IgAN who are at risk for disease progression, irrespective of proteinuria levels. Nefecon® is now a...

December 21, 2023 | News

BioCity Doses First Patient in Phase Ib/II Trial of BC3402 Anti-TIM-3 mAb with IMFINZI for Advanced Hepatocellular Carcinoma

The study is being conducted at Zhongshan Hospital with Prof. Jia Fan as the principal investigator. Dr. Fan is a world-renowned liver cancer sur...

December 21, 2023 | News

Stay Connected